Abstract:Blood-based interferon-gamma (IFN-γ) release assays (IGRAs) have been proven to be useful in the diagnosis of Mycobacterium tuberculosis (Mtb) infection. However, IGRAs have not been recommended for clinical practice in most low-income settings due to cost-intensive limitations and shortage of clinical data available. The established T-SPOT. TB assay containing Mtb-specific antigens ESAT-6 and CFP10 are widely used for immunodiagonsis of Mtb infection, but the high cost is one of the restricting factors against its clinical application in the developing countries. More recently, a cost-saving IGRA assay, TS-SPOT, was approved in China. This new assay contains an additional antigen Rv3615c. Rv3615c contains broadly recognized CD4+ and CD8+ epitopes, and T-cell responses to Rv3615c are as specific for Mtb infection as the responses to ESAT-6 and CFP10 in both Mtb-infected humans and M. bovis-infected cattle. Therefore, we assessed the likely effect of inclusion of Rv3615c as stimulus besides ESAT-6 and CFP10 in an IGRA assay and evaluated the performance of TS-SPOT for diagnosis of Mtb infection and active TB compared with T-SPOT.TB. We tested 155 active TB patients, 90 non-TB lung disease patients, and 55 healthy individuals. The results presented an improved positive rate for diagnosis of active TB and Mtb infection, that could be attributable to inclusion of Rv3615c in the mixture of stimulatory antigens. The diagnostic efficiency of TS-SPOT assay for active TB was as follows: sensitivity 80.00%, specificity 83.45%, positive predictive value (PPV) 83.78%, negative predictive value (NPV) 83.45%, positive likelihood ratio (LR+) 4.83, and negative likelihood ratio (LR-) 0.24. The results were similar to those of T-SPOT.TB, with an excellent agreement (κ = 0.91, 95% CI: 0.85-0.95) being observed between these two assays. The sensitivities of the TS-SPOT assay varied for patients with different forms of active TB, with the highest sensitivity for patients with culture-positive pulmonary TB (92.16%) and the lowest for those with tuberculosis meningitis (50.00%). Taken together, the current evidence indicates that this new TS-SPOT assay is a useful adjunct to the current tests for rapid diagnosis of active TB and Mtb infection in low-income and high-incidence settings due to its characteristics of cost-effectiveness and high-quality.

Preparation of Immunochromatographic Strips for Rapid Detection of Early Secreted Protein ESAT-6 and Culture Filtrate Protein CFP-10 from Mycobacterium Tuberculosis.

Clinical Application and Antigenicity of ESAT-6/CFP-10 Fusion Protein in Diagnosis of Tuberculosis

Novel Monoclonal Antibodies To Esat-6 And Cfp-10 Antigens For Elisa-Based Diagnosis Of Pleural Tuberculosis

High Accuracy of Recombinant Fusion Protein Early Secretory Antigenic Target Protein 6‐culture Filtrate Protein 10 Skin Test for the Detection of Tuberculosis Infection: a Phase III, Multi‐centered, Double‐blind, Hospital‐based, Randomized Controlled Trial

High Accuracy of Recombinant Fusion Protein ESAT6-CFP10 Skin Test for the Detection of Tuberculosis Infection: A Phase III, Multi-centered, Double-blind, Hospital-based, Randomized Controlled Trial

CFP10 and ESAT6 Aptamers As Effective Mycobacterial Antigen Diagnostic Reagents.

Picogram level electrochemical impedimetric immunosensor for monitoring Mycobacterium tuberculosis based on specific and sensitive ESAT-6 monoclonal antibody

The CFP21 Protein-Elispot Method of Diagnosing Mycobacterium Tuberculosis Infection and Its Diagnostic Value

A preliminary evaluation of a new compound multiple antigens for detection of pulmonary tuberculosis by ELISPOT

A New Method of Tuberculosis Infection Diagnosis—Enzyme-Linked Immunospot Assay

Establishment and Preliminary Application of Immunochromatographic Strips for Rapid Detection of Antibodies Against M.bovis

Evaluation of enzyme-linked immunospot assay detecting Mycobacterium tuberculosis specific T cell responses in patients with pulmonary tuberculosis

Early diagnosis of tuberculous meningitis new methods:detection concentration in cerebrospinal fluid CFP-10 and ESAT-6

Evaluation of a New IFN-γ Release Assay for Rapid Diagnosis of Active Tuberculosis in a High-Incidence Setting.

Red Spectral Shift in Sensitive Colorimetric Detection of Tuberculosis by ESAT-6 Antigen-Antibody Complex: a New Strategy with Gold Nanoparticle

Enhanced Serodiagnostic Utility of Novel Mycobacterium Tuberculosis Polyproteins

Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial

Utility of Recombinant Fusion Protein ESAT6-CFP10 Skin Test for Differential Diagnosis of Active Tuberculosis: A Prospective Study.

Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials

[The Comparison of Different Antigens in Enzyme-Linked Immunospot Assay for the Diagnosis of Tuberculosis.].

Fluorescent lateral flow assay strip for Mycobacterium tuberculosis and Mycobacterium smegmatis based on mycobacteriophage tail protein and aptamer